Evermay Wealth Management LLC Has $309,000 Holdings in Celgene Co. (NASDAQ:CELG)

Celgene logo Evermay Wealth Management LLC grew its holdings in Celgene Co. (NASDAQ:CELG) by 13.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,819 shares of the biopharmaceutical company’s stock after buying an additional 556 shares during the quarter. Evermay Wealth Management LLC’s holdings in Celgene were worth $309,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the company. FMR LLC grew its stake in Celgene by 14.8% in the second quarter. FMR LLC now owns 8,160,001 shares of the biopharmaceutical company’s stock valued at $648,067,000 after purchasing an additional 1,051,528 shares during the last quarter. Pensionfund Sabic purchased a new position in Celgene in the third quarter valued at about $2,416,000. Pensionfund DSM Netherlands purchased a new position in Celgene in the third quarter valued at about $3,401,000. Northwest Bancshares Inc. grew its stake in shares of Celgene by 96.2% during the third quarter. Northwest Bancshares Inc. now owns 13,520 shares of the biopharmaceutical company’s stock worth $1,210,000 after acquiring an additional 6,629 shares during the last quarter. Finally, Centre Asset Management LLC purchased a new stake in shares of Celgene during the third quarter worth about $6,347,000. Institutional investors and hedge funds own 72.71% of the company’s stock.

A number of brokerages have recently weighed in on CELG. UBS Group set a $94.00 price target on Celgene and gave the stock a “buy” rating in a research note on Saturday, October 27th. Jefferies Financial Group downgraded Celgene from a “buy” rating to a “hold” rating and set a $95.00 target price for the company. in a report on Friday, February 1st. Wells Fargo & Co decreased their target price on Celgene from $90.00 to $84.00 and set a “market perform” rating for the company in a report on Thursday, January 3rd. Morgan Stanley decreased their target price on Celgene from $93.00 to $88.00 and set an “equal weight” rating for the company in a report on Wednesday, December 19th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $100.00 target price on shares of Celgene in a report on Thursday, January 3rd. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $109.29.

Shares of NASDAQ:CELG opened at $87.91 on Monday. Celgene Co. has a 12-month low of $58.59 and a 12-month high of $97.43. The company has a market capitalization of $61.63 billion, a price-to-earnings ratio of 11.55, a P/E/G ratio of 0.41 and a beta of 1.72. The company has a debt-to-equity ratio of 4.06, a current ratio of 2.13 and a quick ratio of 1.99.

Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, January 31st. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.32 by $0.07. Celgene had a return on equity of 125.35% and a net margin of 26.48%. The company had revenue of $4.04 billion during the quarter, compared to the consensus estimate of $3.98 billion. During the same period in the previous year, the company posted $2.00 earnings per share. On average, sell-side analysts anticipate that Celgene Co. will post 10.01 EPS for the current year.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. Institutional Ownership by Quarter for Celgene (NASDAQ:CELG) Receive News & Ratings for Celgene Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Celgene and related companies with MarketBeat.com’s FREE daily email newsletter .

Click Here to Continue...


Add a Comment

Your email address will not be published. Required fields are marked *